Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

70 results about "Liver Insufficiency" patented technology

Liver failure or hepatic insufficiency is the inability of the liver to perform its normal synthetic and metabolic function as part of normal physiology. Two forms are recognised, acute and chronic.

Quantification method for remaining liver function and novel liver receptor imaging agent

A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.
Owner:INST NUCLEAR ENERGY RES ROCAEC

Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and / or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and / or treating, and for preventing and / or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia. The present invention further relates to methods for inducing the regeneration of cells, tissues, organs and organic systems such as the circulatory, nervous and endocrine systems. Finally, the present invention relates to methods for restoring immune response in an animal, in particular a human being.
Owner:NOWILL ALEXANDRE EDUARDO

Systems and methods for treating chronic liver failure based on peritoneal dialysis

An artificial liver system for treating liver failure includes a reservoir to provide albumin-containing dialysis fluid to the patient's peritoneum, an implantable device including a pump to pump the fluid from the peritoneum to the bladder via respective catheters, control circuitry, battery and transceiver; a charging and communication system configured to periodically charge the battery and communicate with the implantable device to retrieve data reflective of the patient's health; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable device and charging and communication system. The monitoring and control software allows a treating physician to remotely adjust the volume, time, and frequency with which fluid is pumped from the peritoneal cavity to the bladder based on the data reflective of the patient's health.
Owner:SEQUANA MEDICAL NV

Chinese traditional medicine prescription for treating osteoporosis

InactiveCN101112445AComprehensive curative effectRealize the purpose of western medicine calcium supplementationSkeletal disorderPlant ingredientsOysterRhizome
The present invention relates to a compound preparation in the field of traditional Chinese medicine, in particular to a drug formulation for treating osteoporosis. The present invention includes the following raw materials with the parts by weight: 200 to 1200 parts of radix rehmanniae preparata, 100 to 600 parts of desertliving cistanche, 50 to 500 parts of epimedium herb, 100 to 600 parts of Chinese pyrola herb, 100 to 600 parts of fortune's drynaria rhizome, 100 to 600 parts of himalayan teasel root, 100 to 600 parts of east Asian tree fern rhizome, 100 to 600 parts of eucommia bark, 100 to 1200 parts of membranous milkvetch root, 50 to 500 parts of angelica, 100 to 1000 parts of tuber fleeceflower root, 100 to 1000 parts of suberect spatholobus stem, 100 to 600 parts of Chinese taxillus twig, 50 to 600 parts of Chinese clematis root, 100 to 600 parts of largehead atractylodes rhizome, 50 to 600 parts of twotooth achyranthes root, 100 to 600 parts of barbary wolfberry fruit, 100 to 600 parts of cornu cervi degelatinatum, 100 to 600 parts of medicinal indianmulberry root, 50 to 400 parts of liquoric root and 200 to 2000 parts of oyster. The traditional Chinese medicine preparation of the present invention mainly cures kidney and liver insufficiency, malnutrition of bones and tendons and blood stasis blocking syndromes; and the syndromes are pains at the waist and the back, weak legs and pains etc. The present invention is mainly applicable to the people with the symptoms of osteoporosis. The present invention has reliable efficacy and no adverse reactions, which is proved by the clinical applications.
Owner:毛继凯

Application of fructus forsythiae aglycone in preparing medicament for preventing or treating liver injury or liver failure

The invention discloses application of fructus forsythiae aglycone in preparing a medicament for preventing or treating liver injury or liver failure, and belongs to the medical field. The fructus forsythiae aglycone is a traditional Chinese medicine monomer obtained by extracting from the conventional fructus forsythiae, and is shown to have better treatment effect for the liver injury caused by acetaminopben, the livery injury caused by anti-tumor drug cis-platinum, acute or chronic livery injury caused by carbon tetrachloride, the livery injury caused by D-galactosamine and the liver failure caused by the D-galactosamine and lipopolysaccharide according to an animal test, has effect, which is better than that of fructus forsythiae and fructus forsythiae aglycone, in treating liver injury or liver failure. The fructus forsythiae aglycone is exact in curative effect and low in side effect for treating the liver injury and the liver failure, and has wide medical application prospect.
Owner:LUNAN PHARMA GROUP CORPORATION

Pediococcus pentosaceus and application thereof

The invention discloses pediococcus pentosaceus and application thereof. The Latin name of the pediococcus pentosaceus is Pediococcus pentosaceus LI05, and the pediococcus pentosaceus is preserved in the China General Microbiological Culture Collection Center and has a preservation number of CGMCC No.7049. The pediococcus pentosaceus disclosed by the invention has the morphological characteristics that the thallus is rod-shaped, dose not generate spores, does not have motility, and has masculine Gram staining. The whole-cell fatty acid of the pediococcus pentosaceus disclosed by the invention comprises the following main components in percentage by weight: about 1.45% of 14:0, about 3.26% of 16:1w7c / 16:1w6c, about 31.25% of 16:0, about 6.31% of 18:1w9c, about 38.59% of 18:1w7c, about 1.37% of 18:0 and about 14.59% of un18.846 / 19:1w6c. The invention also discloses a complete sequence of 16S ribosome DNA (16SrDNA) of the pediococcus pentosaceus. The pediococcus pentosaceus and a preparation thereof disclosed by the invention can be used for adjusting the micro-ecological balance of intestinal tracts of human or animals, promoting digestive absorption and slowing down the happening and development of liver failure of experimental animals.
Owner:ZHEJIANG UNIV

Isolated liver stem cells

ActiveCN101356264AReduce riskTissue cultureProgenitorAdult liver
The present invention relates to isolated liver progenitor stem cells, and cell population thereof, wherein said progenitor stem cells originate from adult liver, esp. of human. The present invention also relates to the use of said isolated progenitor stem cells in medicine, hepatology, inborn errors of liver metabolism, transplantation, infectious diseases, liver failure. The present invention also relates to methods of isolating these cells, their culture, characterization before and after differentiation, and their use for transplantation, animal models of human disease, toxicology and pharmacology.
Owner:UNIVERSITE CATHOLIQUE DE LOUVAIN

Liver support system

An artificial, extracorporeal system for liver replacement and / or assistance, comprises a liver dialysis device for conducting hemodialysis on a patient suffering from liver failure. The liver dialysis device comprises a first standard hollow fiber membrane dialyzer which does not allow passage of an essential amount of albumin over the membrane wall and which is perfused with the patient's blood, and a second hollow fiber membrane dialyzer which allows the passage of essential but defined amounts of albumin over the membrane wall and which receives the blood of the first standard hemodialyzer. The filtrate space is closed off from the lumen space of the hollow fibers and is populated by adsorbent material which may comprise one or more different adsorbents.
Owner:GAMBRO LUNDIA AB

Differentiated human liver cell cultures and their use in bioartificial liver systems

The present invention concerns human hepatocyte cell line cultures and their use in bioartificial liver (BAL) systems. These systems are used to treat subjects suffering from liver failure to temporarily compensate for loss of hepatocellular function and generally comprise a bioreactor loaded with functional liver cells. Until now, it has been problematic to acquire cells with a broad spectrum metabolic functionality, resembling that of freshly isolated human hepatocytes, to the extent that they are in fact suitable for successful clinical BAL application The present inventors have managed to develop human hepatocyte cell line cultures that display broad-spectrum metabolic functionality such as to render them particularly suitable for effective clinical BAL application.
Owner:ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT

Isolated Liver Stem Cells

Isolated liver progenitor stem cells and cell populations of isolated liver progenitor stem cells are disclosed. The progenitor stem cells originate from adult liver, especially human adult liver. The isolated progenitor stem cells have uses in medicine, hepatology, inborn errors of liver metabolism transplantation, infectious diseases and liver failure. Methods of isolating these cells and their culture is described. The isolated cells are characterized before and after differentiation. Their use for transplantation and as animal models of human disease, toxicology and pharmacology is disclosed.
Owner:UNIVERSITE CATHOLIQUE DE LOUVAIN

Isolated liver stem cells

Isolated liver progenitor stem cells and cell populations of isolated liver progenitor stem cells are disclosed. The progenitor stem cells originate from adult liver, especially human adult liver. The isolated progenitor stem cells have uses in medicine, hepatology, inborn errors of liver metabolism transplantation, infectious diseases and liver failure. Methods of isolating these cells and their culture is described. The isolated cells are characterized before and after differentiation. Their use for transplantation and as animal models of human disease, toxicology and pharmacology is disclosed.
Owner:UNIVERSITE CATHOLIQUE DE LOUVAIN

Traditional Chinese medicine for regulating liver regeneration and prevention and treatment method by using same

The invention discloses a compound composition of traditional Chinese medicine granules for regulating liver regeneration and prevention and treatment methods for chronic liver diseases by using the compound alone or in combination with antiviral medicine. The medicine is composed of: 5-30 parts of prepared Chinese foxglove root, 5-30 parts of virgate wormwood, 3-9 parts of turmeric, 3-12 parts of licorice, 3-15 parts of schisandra fruit, 5-15 parts of underleaf pearl, 5-30 parts of diffusa , 5-30 parts of poria, 5-30 parts of coix seed, 5-30 parts of salvia fruit, 1-10 parts of curcuma rhizome, 3-12 parts of dodder, and 5-15 parts of mistletoe For people suffering from chronic liver diseases (drug-induced liver disease, alcoholic or non-alcoholic fatty liver disease, autoimmune liver disease, viral hepatitis, etc.) which have high risk of liver failure, liver cirrhosis, and liver cancer, and people suffering from liver cancer or people after liver cancer surgery, clinical and experimental evidences show that the traditional Chinese medicine granules have synergies of regulation of liver regeneration and anti-virus, anti-liver injury, anti-liver fibrosis, and liver cancer prevention, and a relatively high level of clinical evidence based medicine evidences are obtained.
Owner:李瀚旻

Liver organoid compositions and methods of making and using same

Disclosed are methods of inducing formation of a liver organoid from precursor cells, such as iPSC cells. The disclosed liver organoids may be used for screening for a serious adverse event (SAE), such as liver failure and / or drug induced liver injury (DILI), and / or drug toxicity. The disclosed liver organoids may also be used to treat an individual having liver damage, or for identifying a preferred therapeutic agent.
Owner:JAPAN SCI & TECH CORP

Use of long-acting human recombined soluble TNF alpha receptor in preparation of medicament for treating liver failure

The invention relates to a method for preparing recombine soluble cancer necrotic factor alpha acceptor (Hus TNFR) gene drug. Wherein, the invention uses I or II type long-effect recombine soluble cancer necrotic factor alpha acceptor, via acute, sub acute liver exhaustion animal mode, to predict the liver exhaustion of mouse, and the result proves that it can prolong 10 times of semi-exhaustion period, with better treatment effect, then non-long-effect HusTNFR.
Owner:李海

Methods of treatment with selective EP4 receptor agonists

The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the patient a therapeutically effective amount of a selective EP4 receptor agonist of Formula Ior a prodrug thereof, a pharmaceutically acceptable salt of the selective EP4 receptor agonist or prodrug or a stereoisomer or diastereomeric mixture of the EP4 receptor agonist, prodrug or salt, wherein the variables X, Z, Q, , and R2 are as defined in the specification.
Owner:PFIZER INC

Human umbilical cord mesenchymal stem cell injection, preparation method and application thereof

The invention provides a human umbilical cord mesenchymal stem cell injection, which is composed of human umbilical cord mesenchymal stem cells and a cryopreservation liquid. The cryopreservation liquid is composed of human serum albumin, clinical dimethyl sulfoxide and a compound electrolyte injection. The living cell density of the human umbilical cord mesenchymal stem cell injection is controlled at 0.5*10<6>-2*10<6> / ml, so that the cell viability of the human umbilical cord mesenchymal stem cell injection after cryopreservation and resuscitation can still reach 90% or above, and the treatment effect is facilitated; the content of the human albumin and the content of the clinical dimethyl sulfoxide are controlled to be 3-20% and 5-10% respectively, so that the human umbilical cord mesenchymal stem cell injection can be directly used for injection, can still be safely used after being cryopreserved for at least 72 hours, and is beneficial to achievement of a good treatment effect. The invention also provides a preparation method of the human umbilical cord mesenchymal stem cell injection and application of the human umbilical cord mesenchymal stem cell injection in treatment of liver failure.
Owner:SHANGHAI CRYOWISE MEDICAL TECH CO LTD

Nitrogen-rich carbon sphere adsorbent for whole blood perfusion and preparation method thereof

PendingCN111111616AHelp formPlay the role of heat resistance and non-meltingOther blood circulation devicesOther chemical processesMicrosphereDrug poisoning
The invention provides a nitrogen-rich carbon sphere adsorbent for whole blood perfusion and a preparation method thereof. The adsorbent disclosed by the invention is prepared by carrying out pre-oxidation and carbonization treatment on nitrogen-containing copolymer microspheres with a cross-linked porous structure. The prepared nitrogen-rich carbon sphere adsorbent for whole blood perfusion is good in hydrophilicity, high in blood compatibility and suitable for whole blood perfusion; the prepared nitrogen-rich carbon sphere adsorbent for whole blood perfusion is high in mechanical strength and high in use safety. The prepared nitrogen-rich carbon sphere adsorbent for whole blood perfusion can be applied to the fields of drug poisoning, liver failure, renal failure, immune adsorption and the like, and has relatively high adsorption and removal performance on protein-bound toxoid (such as indol sulfate, p-cresol sulfate, bilirubin, bile acid and the like).
Owner:刘云晖

Liposome, dispersion liquid containing liposome, and preparation methods and application of liposome and dispersion liquid

The invention relates to the field of medical treatment, in particular to lipidosome, dispersion liquid containing the lipidosome, and preparation methods and application of the lipidosome and the dispersion liquid. The lipidosome provided by the invention comprises phospholipid, a liquidity buffer agent and linoleic acid. The lipidosome provided by the invention comprises linoleic acid; and through modification of the lipidosome by linoleic acid, the lipidosome has effectively improved clearing effect on protein binding toxoids related to uremia and liver failure; and when the lipidosome is applied to dialysate in the blood purification therapy, the lipidosome has the advantages of high efficiency, relatively low cost and the like.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Treatment of necroptosis

The present invention derives from the unexpected finding that necroptosis is a novel biomarker and target for therapy in patients with liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). RIPK1, MLKL or RIPK3 can be detected and quantified in serum or plasma, and used as a biomarker for outcome in ACLF and other diseases involving aberrant necroptosis. By antagonising RIPK1, MLKL or RIPK3 many of the unwanted consequences or symptoms of acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL and RIPK3 that may be used in the treatment or prevention of ACLF. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL or RIPK3 that may be used in the treatment or prevention of aberrant necroptosis in the kidney, brain, liver or other organ of the body.
Owner:JALAN RAJIV +3

Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and / or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and / or treating, and for preventing and / or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia. The present invention further relates to methods for inducing the regeneration of cells, tissues, organs and organic systems such as the circulatory, nervous and endocrine systems. Finally, the present invention relates to methods for restoring immune response in an animal, in particular a human being.
Owner:NOWILL ALEXANDRE EDUARDO

Preparation method of UCMSC (umbilical cord mesenchymal stem cell) modified with HGF (hepatocyte growth factor) gene and used for treating liver failure

The invention discloses a preparation method of a UCMSC (umbilical cord mesenchymal stem cell) modified with an HGF (hepatocyte growth factor) gene. The method comprises steps as follows: A) cloning of the HGF gene; B) preparation of a shuttle plasmid containing an HGF target gene; C) establishment of an HGF-containing replication-deficient adenovirus Ad-HGF; D) preparation of the UCMSC which is modified with the gene and over-expresses HGFs. The adenovirus packaged with the HGF gene is used for infecting the UCMSC, and the UCMSC which is modified with the gene and over-expresses the HGFs can be effectively prepared.
Owner:SHENZHEN BEIKE BIOTECH

Application of glycoside compound in preparation of medicine for treating acute liver failure

The invention belongs to the field of medicines, and provides a medicine for treating acute liver failure. The invention discovers that a compound kinsenoside (Kinsenoside(3-(R)-3-beta-D-Glucopyranosyloxybutanolide) can effectively prevent the development of acute liver failure, and in a mouse liver failure model, the compound has the activities of improving liver function and oxidative stress injury, and reducing inflammatory factor secretion and the like; and meanwhile, hepatic cell apoptosis is inhibited by protecting the structural integrity of mitochondria, so that the compound has remarkable liver protection activity and can be used as a medicine for treating the acute liver failure for treating the acute liver failure.
Owner:HUAZHONG UNIV OF SCI & TECH

Treatment of pyroptosis

The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1α) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1α) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of aberrant pyroptosis in the kidney, brain, liver or other organ of the body.
Owner:JALAN RAJIV +3

Use of ARC for inhibiting cell death during liver failure

The invention refers to the use of a polynucleotide encoding “apoptosis repressor with caspase recruitment domain” (ARC) or a functional fragment thereof, and / or an ARC polypeptide or a functional fragment thereof for inhibiting cell death of a liver cell, in particular during liver failure.
Owner:MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN

A Schisandra chinensis vine stem extract has new application in preparing medicine and health product

The invention belongs to the technical field of medicine and mainly discloses the preparation of Schisandra chinensis vine stem extract and the application thereof in the treatment of liver injury. The experimental results show that the extract of Schisandra chinensis vine stem is economical, time-saving, suitable for technological production, and easy to use. Pharmacodynamic studies have shown that the extract has significant protective effects on mice with severe liver injury and liver failure induced by paracetamol (also known as acetaminophen) overdose. Therefore, the active ingredient canbe used to prepare medicine, health product, food additive, compound preparation and the like for protecting liver. The medicine or health product can be any existing dosage form, such as tablet, capsule, powder injection, injection, pill, soft capsule, granule and patch, etc.
Owner:JILIN AGRICULTURAL UNIV

Dipeptide derivative for improving liver function, and its application

The invention provides a dipeptide derivative for improving liver function, and its application, specifically an N-substituted 2(1H) dipeptide derivative and its pharmaceutically acceptable salt, and pharmaceutical composition containing the compound. The compound can effectively improve liver function, to lower alanine aminotransferase (ALT), aspartate aminotransferase (AST) and / or total bilirubin (Tbil). The compound can greatly improve survival rate of liver failure patient.
Owner:BEIJING CONTINENT PHARM CO LTD

Oligonucleotide targeting strategy for hbv cccdna

The present disclosure provides oligonucleotide compositions that target the covalently closed circular (ccc) DNA of hepatitis B virus (HBV). Also disclosed herein are methods for treating a subject diagnosed with, or suspected of having an HBV infection and / or an HBV-associated disorder, e.g., chronic hepatitis B infection, liver failure or cirrhosis and hepatocellular carcinoma.
Owner:JANSSSEN BIOPHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products